SAT-742 - Real-world biochemical effectiveness in patients with XLH treated with burosumab or phosphate and vitamin D

Senior Author/Primary Investigator(s)

• DH

  Dieter Haffner, n/a

  Hannover Medical School
  Hannover, Germany

Late-Breaking Poster Presenter(s)

• 

  Erik A. Imel, MD

  Professor
  Indiana University School of Medicine
  Indianapolis, Indiana, United States

Co-Author(s)

• KO

  Keiichi Ozono, MD

  ISEIKAI International General Hospital
  Osaka, Japan
• MB

  Maria Luisa Brandi, n/a

  20132
  Milan, Italy
• PF

  Pablo Florenzano, MD

  Associate Professor
  Pontificia Universidad Católica de Chile
  Santiago, Chile
• TC

  Thomas O. Carpenter, n/a

  Yale University School of Medicine
  New Haven, United States
• SF

  Shannon Ferrante, n/a

  Kyowa Kirin Inc
  Princeton, New Jersey, United States
• ZL

  Zhiyi Li, MBA, MA

  Director
  Kyowa Kirin Inc
  Princeton, New Jersey, United States
• KS

  Kerry Sandilands, n/a

  Kyowa Kirin International Plc
  Marlow, United Kingdom
• PV

  Paul Vandewalle, n/a

  Kyowa Kirin Co. Ltd.
  Madrid, Spain
• CL

  Cheuk Lee, n/a

  Kyowa Kirin International Plc
  Marlow, United Kingdom
• MK

  Masanori Kanematsu, n/a

  Kyowa Kirin Co. Ltd.
  Tokyo, Japan
• KM

  Keith McCullough, n/a

  Arbor Research Collaborative for Health
  Ann Arbor, United States
• KH

  Kieran Hawthorne, n/a

  Arbor Research Collaborative for Health
  Ann Arbor, United States
• SF

  Seiji Fukumoto, n/a

  Tamaki – Aozora Hospital
  Tokushima, Japan